Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C24H34O4 |
| Molecular Weight | 386.5244 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])C[C@H](C)C4=CC(=O)CC[C@]34C
InChI
InChIKey=PSGAAPLEWMOORI-PEINSRQWSA-N
InChI=1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1
| Molecular Formula | C24H34O4 |
| Molecular Weight | 386.5244 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Medroxyprogesterone acetate (INN, USAN, BAN), also known as 17α-hydroxy-6α-methylprogesterone acetate, and commonly abbreviated as MPA, is a steroidal progestin, a synthetic variant of the human hormone progesterone. Medroxyprogesterone acetate (MPA) administered orally or parenterally in the recommended doses to women with adequate endogenous estrogen, transforms proliferative into secretory endometrium. Androgenic and anabolic effects have been noted, but the drug is apparently devoid of significant estrogenic activity. While parenterally administered MPA inhibits gonadotropin production, which in turn prevents follicular maturation and ovulation, available data indicate that this does not occur when the usually recommended oral dosage is given as single daily doses. MPA is a more potent derivative of its parent compound medroxyprogesterone (MP). While medroxyprogesterone is sometimes used as a synonym for medroxyprogesterone acetate, what is normally being administered is MPA and not MP. Used as a contraceptive and to treat secondary amenorrhea, abnormal uterine bleeding, pain associated with endometriosis, endometrial and renal cell carcinomas, paraphilia in males, GnRH-dependent forms of precocious puberty, as well as to prevent endometrial changes associated with estrogens. Progestins diffuse freely into target cells in the female reproductive tract, mammary gland, hypothalamus, and the pituitary and bind to the progesterone receptor. Once bound to the receptor, progestins slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH surge.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL208 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | PROVERA Approved UseMedroxyprogesterone Acetate Tablets USP are a progestin indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. Medroxyprogesterone Acetate Tablets USP are also indicated to reduce the incidence of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving daily oral conjugated estrogens 0.625 mg tablets. Launch Date1959 |
|||
| Primary | PROVERA Approved UseMedroxyprogesterone Acetate Tablets USP are a progestin indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. Medroxyprogesterone Acetate Tablets USP are also indicated to reduce the incidence of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving daily oral conjugated estrogens 0.625 mg tablets. Launch Date1959 |
|||
| Preventing | PROVERA Approved UseMedroxyprogesterone Acetate Tablets USP are a progestin indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. Medroxyprogesterone Acetate Tablets USP are also indicated to reduce the incidence of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving daily oral conjugated estrogens 0.625 mg tablets. Launch Date1959 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
0.71 ng/mL |
10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
MEDROXYPROGESTERONE ACETATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
6.01 ng × h/mL |
10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
MEDROXYPROGESTERONE ACETATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
16.6 h |
10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
MEDROXYPROGESTERONE ACETATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
10% |
10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
MEDROXYPROGESTERONE ACETATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
Doses
| Dose | Population | Adverse events |
|---|---|---|
150 mg 3 times / month multiple, intramuscular Recommended Dose: 150 mg, 3 times / month Route: intramuscular Route: multiple Dose: 150 mg, 3 times / month Sources: Page: p.7 |
healthy, 15 - 51 n = 3900 Health Status: healthy Condition: Prevention of pregnancy Age Group: 15 - 51 Sex: F Population Size: 3900 Sources: Page: p.7 |
Disc. AE: Bleeding, Amenorrhea... AEs leading to discontinuation/dose reduction: Bleeding (8.2%) Sources: Page: p.7Amenorrhea (2.1%) Weight gain (2%) |
20 mg 1 times / day multiple, oral Highest studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Co-administed with:: E2V, p.o(2 mg; q.d) Sources: Page: p.12 |
healthy, 45-66 n = 132 Health Status: healthy Condition: Postmenopause Age Group: 45-66 Sex: F Population Size: 132 Sources: Page: p.12 |
Disc. AE: Bleeding, Uterine fibroids... AEs leading to discontinuation/dose reduction: Bleeding (3.8%) Sources: Page: p.12Uterine fibroids (2.3%) Gallstones (0.76%) Endometrial polyp (0.76%) |
2.5 mg 1 times / day multiple, oral Studied dose Dose: 2.5 mg, 1 times / day Route: oral Route: multiple Dose: 2.5 mg, 1 times / day Co-administed with:: conjugated estrogens, p.o(0.625 mg; q.d) Sources: Page: p.1325 |
healthy, 45-79 n = 284 Health Status: healthy Condition: Postmenopause Age Group: 45-79 Sex: F Population Size: 284 Sources: Page: p.1325 |
Disc. AE: Bleeding vaginal... AEs leading to discontinuation/dose reduction: Bleeding vaginal (9%) Sources: Page: p.1325 |
10 mg 1 times / day multiple, oral (max) Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Co-administed with:: conjugated estrogens, p.o(0.625 mg; q.d) Sources: Page: p.1, p.5 |
healthy, 50 -79 n = 8506 Health Status: healthy Condition: Postmenopause Age Group: 50 -79 Sex: F Population Size: 8506 Sources: Page: p.1, p.5 |
Disc. AE: Myocardial infarction, Stroke... AEs leading to discontinuation/dose reduction: Myocardial infarction Sources: Page: p.1, p.5Stroke Breast cancer invasive NOS Embolism pulmonary Deep vein thrombosis |
10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: Page: p.628 |
unhealthy, >18 n = 83 Health Status: unhealthy Condition: Idiopathic heavy menstrual bleeding Age Group: >18 Sex: F Population Size: 83 Sources: Page: p.628 |
Disc. AE: Dizziness, Fluid retention... AEs leading to discontinuation/dose reduction: Dizziness (1.2%) Sources: Page: p.628Fluid retention (1.2%) |
2.5 mg 1 times / day multiple, oral Studied dose Dose: 2.5 mg, 1 times / day Route: oral Route: multiple Dose: 2.5 mg, 1 times / day Co-administed with:: conjugated estrogens, p.o(0.625 mg; q.d) Sources: Page: p.1, p.5 |
healthy, >65 Health Status: healthy Condition: Postmenopause Age Group: >65 Sex: F Sources: Page: p.1, p.5 |
Disc. AE: Dementia... AEs leading to discontinuation/dose reduction: Dementia Sources: Page: p.1, p.5 |
10 mg 1 times / day multiple, oral (max) Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Secondary Amenorrhea|Abnormal Uterine Bleeding Due to Hormonal Imbalance Sex: F Sources: Page: p.1 |
Disc. AE: Cardiovascular disorder... AEs leading to discontinuation/dose reduction: Cardiovascular disorder Sources: Page: p.1 |
150 mg 3 times / month multiple, intramuscular Recommended Dose: 150 mg, 3 times / month Route: intramuscular Route: multiple Dose: 150 mg, 3 times / month Sources: Page: p.1 |
healthy Health Status: healthy Condition: Prevention of pregnancy Sex: F Sources: Page: p.1 |
Disc. AE: Bone density abnormal... AEs leading to discontinuation/dose reduction: Bone density abnormal Sources: Page: p.1 |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Weight gain | 2% Disc. AE |
150 mg 3 times / month multiple, intramuscular Recommended Dose: 150 mg, 3 times / month Route: intramuscular Route: multiple Dose: 150 mg, 3 times / month Sources: Page: p.7 |
healthy, 15 - 51 n = 3900 Health Status: healthy Condition: Prevention of pregnancy Age Group: 15 - 51 Sex: F Population Size: 3900 Sources: Page: p.7 |
| Amenorrhea | 2.1% Disc. AE |
150 mg 3 times / month multiple, intramuscular Recommended Dose: 150 mg, 3 times / month Route: intramuscular Route: multiple Dose: 150 mg, 3 times / month Sources: Page: p.7 |
healthy, 15 - 51 n = 3900 Health Status: healthy Condition: Prevention of pregnancy Age Group: 15 - 51 Sex: F Population Size: 3900 Sources: Page: p.7 |
| Bleeding | 8.2% Disc. AE |
150 mg 3 times / month multiple, intramuscular Recommended Dose: 150 mg, 3 times / month Route: intramuscular Route: multiple Dose: 150 mg, 3 times / month Sources: Page: p.7 |
healthy, 15 - 51 n = 3900 Health Status: healthy Condition: Prevention of pregnancy Age Group: 15 - 51 Sex: F Population Size: 3900 Sources: Page: p.7 |
| Endometrial polyp | 0.76% Disc. AE |
20 mg 1 times / day multiple, oral Highest studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Co-administed with:: E2V, p.o(2 mg; q.d) Sources: Page: p.12 |
healthy, 45-66 n = 132 Health Status: healthy Condition: Postmenopause Age Group: 45-66 Sex: F Population Size: 132 Sources: Page: p.12 |
| Gallstones | 0.76% Disc. AE |
20 mg 1 times / day multiple, oral Highest studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Co-administed with:: E2V, p.o(2 mg; q.d) Sources: Page: p.12 |
healthy, 45-66 n = 132 Health Status: healthy Condition: Postmenopause Age Group: 45-66 Sex: F Population Size: 132 Sources: Page: p.12 |
| Uterine fibroids | 2.3% Disc. AE |
20 mg 1 times / day multiple, oral Highest studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Co-administed with:: E2V, p.o(2 mg; q.d) Sources: Page: p.12 |
healthy, 45-66 n = 132 Health Status: healthy Condition: Postmenopause Age Group: 45-66 Sex: F Population Size: 132 Sources: Page: p.12 |
| Bleeding | 3.8% Disc. AE |
20 mg 1 times / day multiple, oral Highest studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Co-administed with:: E2V, p.o(2 mg; q.d) Sources: Page: p.12 |
healthy, 45-66 n = 132 Health Status: healthy Condition: Postmenopause Age Group: 45-66 Sex: F Population Size: 132 Sources: Page: p.12 |
| Bleeding vaginal | 9% Disc. AE |
2.5 mg 1 times / day multiple, oral Studied dose Dose: 2.5 mg, 1 times / day Route: oral Route: multiple Dose: 2.5 mg, 1 times / day Co-administed with:: conjugated estrogens, p.o(0.625 mg; q.d) Sources: Page: p.1325 |
healthy, 45-79 n = 284 Health Status: healthy Condition: Postmenopause Age Group: 45-79 Sex: F Population Size: 284 Sources: Page: p.1325 |
| Breast cancer invasive NOS | Disc. AE | 10 mg 1 times / day multiple, oral (max) Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Co-administed with:: conjugated estrogens, p.o(0.625 mg; q.d) Sources: Page: p.1, p.5 |
healthy, 50 -79 n = 8506 Health Status: healthy Condition: Postmenopause Age Group: 50 -79 Sex: F Population Size: 8506 Sources: Page: p.1, p.5 |
| Deep vein thrombosis | Disc. AE | 10 mg 1 times / day multiple, oral (max) Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Co-administed with:: conjugated estrogens, p.o(0.625 mg; q.d) Sources: Page: p.1, p.5 |
healthy, 50 -79 n = 8506 Health Status: healthy Condition: Postmenopause Age Group: 50 -79 Sex: F Population Size: 8506 Sources: Page: p.1, p.5 |
| Embolism pulmonary | Disc. AE | 10 mg 1 times / day multiple, oral (max) Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Co-administed with:: conjugated estrogens, p.o(0.625 mg; q.d) Sources: Page: p.1, p.5 |
healthy, 50 -79 n = 8506 Health Status: healthy Condition: Postmenopause Age Group: 50 -79 Sex: F Population Size: 8506 Sources: Page: p.1, p.5 |
| Myocardial infarction | Disc. AE | 10 mg 1 times / day multiple, oral (max) Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Co-administed with:: conjugated estrogens, p.o(0.625 mg; q.d) Sources: Page: p.1, p.5 |
healthy, 50 -79 n = 8506 Health Status: healthy Condition: Postmenopause Age Group: 50 -79 Sex: F Population Size: 8506 Sources: Page: p.1, p.5 |
| Stroke | Disc. AE | 10 mg 1 times / day multiple, oral (max) Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Co-administed with:: conjugated estrogens, p.o(0.625 mg; q.d) Sources: Page: p.1, p.5 |
healthy, 50 -79 n = 8506 Health Status: healthy Condition: Postmenopause Age Group: 50 -79 Sex: F Population Size: 8506 Sources: Page: p.1, p.5 |
| Dizziness | 1.2% Disc. AE |
10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: Page: p.628 |
unhealthy, >18 n = 83 Health Status: unhealthy Condition: Idiopathic heavy menstrual bleeding Age Group: >18 Sex: F Population Size: 83 Sources: Page: p.628 |
| Fluid retention | 1.2% Disc. AE |
10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: Page: p.628 |
unhealthy, >18 n = 83 Health Status: unhealthy Condition: Idiopathic heavy menstrual bleeding Age Group: >18 Sex: F Population Size: 83 Sources: Page: p.628 |
| Dementia | Disc. AE | 2.5 mg 1 times / day multiple, oral Studied dose Dose: 2.5 mg, 1 times / day Route: oral Route: multiple Dose: 2.5 mg, 1 times / day Co-administed with:: conjugated estrogens, p.o(0.625 mg; q.d) Sources: Page: p.1, p.5 |
healthy, >65 Health Status: healthy Condition: Postmenopause Age Group: >65 Sex: F Sources: Page: p.1, p.5 |
| Cardiovascular disorder | Disc. AE | 10 mg 1 times / day multiple, oral (max) Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Secondary Amenorrhea|Abnormal Uterine Bleeding Due to Hormonal Imbalance Sex: F Sources: Page: p.1 |
| Bone density abnormal | Disc. AE | 150 mg 3 times / month multiple, intramuscular Recommended Dose: 150 mg, 3 times / month Route: intramuscular Route: multiple Dose: 150 mg, 3 times / month Sources: Page: p.1 |
healthy Health Status: healthy Condition: Prevention of pregnancy Sex: F Sources: Page: p.1 |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| moderate [IC50 16.1 uM] | ||||
| slight [IC50 >100 uM] | ||||
| slight [IC50 >100 uM] | ||||
| slight [IC50 >100 uM] | ||||
| slight [IC50 >100 uM] | ||||
| weak [IC50 31.5 uM] | ||||
| yes | ||||
| yes |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| yes | likely (co-administration study) Comment: Drugs or herbal products that induce certain enzymes, including CYP3A4, may decrease the effectiveness of contraceptive drug products. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Pulmonary lymphangioleiomyomatosis: presentation and results of treatment]. | 2001 |
|
| Organ preserving method in the management of atypical endometrial hyperplasia. | 2001 |
|
| Quantitative evaluation of collagen and muscle fibers in the lower urinary tract of castrated and under-hormone replacement female rats. | 2001 |
|
| Effect of medroxyprogesterone pretreatment on pentagastrin-induced panic symptoms in females with panic disorder. | 2001 Apr 15 |
|
| Effects of hormone replacement therapy on cognitive performance in elderly women. | 2001 Apr 20 |
|
| [A case of pulmonary lymphangioleiomyomatosis originally treated as bronchial asthma]. | 2001 Aug |
|
| Rat uterine complement C3 expression as a model for progesterone receptor modulators: characterization of the new progestin trimegestone. | 2001 Aug |
|
| Effects of hormone replacement therapy on endocrine and spirometric parameters in asthmatic postmenopausal women. | 2001 Aug |
|
| Thoracic endometriosis syndrome resembling pulmonary embolism. | 2001 Aug |
|
| Bone marrow failure from medication error: diagnosis by history, not biopsy. | 2001 Aug 13-27 |
|
| Transdermal hormone replacement therapy in postmenopausal women with uterine leiomyomas. | 2001 Dec |
|
| Urinary tract infections in postmenopausal women: effect of hormone therapy and risk factors. | 2001 Dec |
|
| Hormone replacement therapy and endothelial function: the exception that proves the rule? | 2001 Dec |
|
| Hormone replacement therapy and endothelial function. Results of a randomized controlled trial in healthy postmenopausal women. | 2001 Dec |
|
| How to use progestin in hormone replacement therapy: an animal experiment. | 2001 Feb |
|
| Estrogen improves impaired musculocutaneous vascular adrenergic reactivity in pharmacologically ovariectomized rats: a potential peripheral mechanism for hot flashes? | 2001 Feb |
|
| [Advanced breast cancer with multiple bone metastases successfully treated with combined chemoendocrine-therapy of CEF (cyclophosphamide, epirubicin, 5-fluorouracil) and 5'-DFUR (5'-deoxy-5-fluorouridine) + MPA (medroxyprogesterone acetate)--a case report]. | 2001 Feb |
|
| Monthly injection provides new contraceptive choice. | 2001 Jan-Feb |
|
| Hormonal and barrier contraception and risk of upper genital tract disease in the PID Evaluation and Clinical Health (PEACH) study. | 2001 Jul |
|
| Changes in quality of life after hormonal treatment of endometriosis. | 2001 Jul |
|
| Diabetes and depot medroxyprogesterone contraception in Navajo women. | 2001 Jul 23 |
|
| Lunelle: a new contraceptive alternative. | 2001 Jun |
|
| The incidence of unrecognized myocardial infarction in women with coronary heart disease. | 2001 Jun 5 |
|
| Increased need for thyroxine in women with hypothyroidism during estrogen therapy. | 2001 Jun 7 |
|
| Hormone replacement therapy in healthy postmenopausal women: a randomized, placebo-controlled study of effects on coagulation and fibrinolytic factors. | 2001 Mar |
|
| [Endometriosis of the abdominal wall: diagnosis and treatment techniques]. | 2001 May |
|
| Dose response effect of cyclical medroxyprogesterone on blood pressure in postmenopausal women. | 2001 May |
|
| Observer variation--how many observers for generalizability? | 2001 May |
|
| Quinacrine non-surgical female sterilization in Bangladesh. | 2001 Nov |
|
| Acute and mid-term combined hormone replacement therapy improves endothelial function in post-menopausal women with angina and angiographically normal coronary arteries. | 2001 Nov |
|
| Anaylsis of birefringence during wound healing and remodeling following alkali burns in rabbit cornea. | 2001 Oct |
|
| Interactions between antiepileptic drugs and hormonal contraception. | 2002 |
|
| Use of medroxyprogesterone acetate in the treatment of Müllerian adenosarcoma: a case report. | 2002 Apr |
|
| Contraceptive efficacy and patient acceptance of Lunelle. | 2002 Aug |
|
| Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women. | 2002 Aug |
|
| High-risk teen compliance with prescription contraception: an analysis of Ohio Medicaid claims. | 2002 Feb |
|
| Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. | 2002 Feb |
|
| Effects of hormonal replacement therapy on oxidative stress and total antioxidant capacity in postmenopausal hemodialysis patients. | 2002 Jan |
|
| Effects of acute hormone therapy on recurrent ischemia in postmenopausal women with unstable angina. | 2002 Jan 16 |
|
| HRT: forever or never? | 2002 Jul-Aug |
|
| Medroxyprogesterone-induced endocrine alterations after menopause. | 2002 Jul-Aug |
|
| Estrogen status correlates with the calcium content of coronary atherosclerotic plaques in women. | 2002 Mar |
|
| Pharmacological characterization of the ATP-dependent low K(m) guanosine 3',5'-cyclic monophosphate (cGMP) transporter in human erythrocytes. | 2002 Mar 1 |
|
| Effect of postmenopausal hormone therapy on cardiovascular risk. | 2002 May |
|
| Hormone replacement therapy: estrogen and progestin effects on plasma C-reactive protein concentrations. | 2002 May |
|
| Effect of medroxyprogesterone on pulmonary arterial pressure, exhaled nitric oxide, ECG and arterial blood gases. | 2002 May |
|
| Contraceptive applications of estrogen. | 2002 May-Jun |
|
| Influence of estradiol and gestagens on oxidative stress in the rat uterus. | 2002 Sep |
|
| Chronic respiratory failure: an unusual cause and treatment. | 2002 Sep |
|
| Effect of hormone replacement therapy on uterine fibroids in postmenopausal women--a 3-year study. | 2002 Sep 30 |
Patents
Sample Use Guides
Secondary Amenorrhea: PROVERA (medroxyprogesterone acetate ) tablets may be given in dosages of 5 or 10 mg daily for 5 to 10 days.
Abnormal Uterine Bleeding Due to Hormonal Imbalance in the Absence of Organic Pathology: Beginning on the calculated 16th or 21st day of the menstrual cycle, 5 or 10 mg of PROVERA may be given daily for 5 to 10 days.
Reduction of Endometrial Hyperplasia in Postmenopausal Women: Receiving Daily 0.625 mg Conjugated Estrogens
Route of Administration:
Oral
Freshly isolated PBMCs (peripheral blood mononuclear cells) from normal blood donors were treated with physiologic MPA (medroxyprogesterone acetate) concentrations ranging from 0.003 to 5 ng/ml and infected with GFP-tagged R5-tropic or X4-tropic HIV-1 pseudoviruses by spinoculation. The infection was limited to a single cycle. Cells were stained with CD3, CD8 and CD14
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:00:43 GMT 2023
by
admin
on
Fri Dec 15 15:00:43 GMT 2023
|
| Record UNII |
C2QI4IOI2G
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
141901
Created by
admin on Fri Dec 15 15:00:43 GMT 2023 , Edited by admin on Fri Dec 15 15:00:43 GMT 2023
|
||
|
IARC | Medroxyprogesterone acetate | ||
|
WHO-ESSENTIAL MEDICINES LIST |
18.3.2
Created by
admin on Fri Dec 15 15:00:44 GMT 2023 , Edited by admin on Fri Dec 15 15:00:44 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
18.7
Created by
admin on Fri Dec 15 15:00:44 GMT 2023 , Edited by admin on Fri Dec 15 15:00:44 GMT 2023
|
||
|
NCI_THESAURUS |
C776
Created by
admin on Fri Dec 15 15:00:43 GMT 2023 , Edited by admin on Fri Dec 15 15:00:43 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
18.3.2 (EST/MED)
Created by
admin on Fri Dec 15 15:00:44 GMT 2023 , Edited by admin on Fri Dec 15 15:00:44 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
21171
Created by
admin on Fri Dec 15 15:00:43 GMT 2023 , Edited by admin on Fri Dec 15 15:00:43 GMT 2023
|
PRIMARY | |||
|
MEDROXYPROGESTERONE ACETATE
Created by
admin on Fri Dec 15 15:00:44 GMT 2023 , Edited by admin on Fri Dec 15 15:00:44 GMT 2023
|
PRIMARY | Description: A white or almost white, crystalline powder. Solubility: Practically insoluble in water; soluble in acetone R and dioxan R; slightly soluble in ethanol (~750 g/L) TS, methanol Rand ether R. Category: Progestogen. Storage: Medroxyprogesterone acetate should be kept in a tight container, protected from light. Definition: Medroxyprogesterone acetate contains not less than 97.0% and not more than the equivalent of 103.0% of C24H34O4,calculated with reference to the dried substance. | ||
|
1000112
Created by
admin on Fri Dec 15 15:00:44 GMT 2023 , Edited by admin on Fri Dec 15 15:00:44 GMT 2023
|
PRIMARY | RxNorm | ||
|
DMPA
Created by
admin on Fri Dec 15 15:00:43 GMT 2023 , Edited by admin on Fri Dec 15 15:00:43 GMT 2023
|
PRIMARY | |||
|
D017258
Created by
admin on Fri Dec 15 15:00:43 GMT 2023 , Edited by admin on Fri Dec 15 15:00:43 GMT 2023
|
PRIMARY | |||
|
26386
Created by
admin on Fri Dec 15 15:00:43 GMT 2023 , Edited by admin on Fri Dec 15 15:00:43 GMT 2023
|
PRIMARY | |||
|
SUB03114MIG
Created by
admin on Fri Dec 15 15:00:43 GMT 2023 , Edited by admin on Fri Dec 15 15:00:43 GMT 2023
|
PRIMARY | |||
|
71-58-9
Created by
admin on Fri Dec 15 15:00:43 GMT 2023 , Edited by admin on Fri Dec 15 15:00:43 GMT 2023
|
PRIMARY | |||
|
SUB127224
Created by
admin on Fri Dec 15 15:00:43 GMT 2023 , Edited by admin on Fri Dec 15 15:00:43 GMT 2023
|
ALTERNATIVE | |||
|
C2QI4IOI2G
Created by
admin on Fri Dec 15 15:00:43 GMT 2023 , Edited by admin on Fri Dec 15 15:00:43 GMT 2023
|
PRIMARY | |||
|
C2QI4IOI2G
Created by
admin on Fri Dec 15 15:00:43 GMT 2023 , Edited by admin on Fri Dec 15 15:00:43 GMT 2023
|
PRIMARY | |||
|
DB00603
Created by
admin on Fri Dec 15 15:00:43 GMT 2023 , Edited by admin on Fri Dec 15 15:00:43 GMT 2023
|
PRIMARY | |||
|
6716
Created by
admin on Fri Dec 15 15:00:43 GMT 2023 , Edited by admin on Fri Dec 15 15:00:43 GMT 2023
|
PRIMARY | |||
|
C1155
Created by
admin on Fri Dec 15 15:00:43 GMT 2023 , Edited by admin on Fri Dec 15 15:00:43 GMT 2023
|
PRIMARY | |||
|
100000091612
Created by
admin on Fri Dec 15 15:00:44 GMT 2023 , Edited by admin on Fri Dec 15 15:00:44 GMT 2023
|
PRIMARY | |||
|
m7134
Created by
admin on Fri Dec 15 15:00:43 GMT 2023 , Edited by admin on Fri Dec 15 15:00:43 GMT 2023
|
PRIMARY | Merck Index | ||
|
MEDROXYPROGESTERONE ACETATE
Created by
admin on Fri Dec 15 15:00:44 GMT 2023 , Edited by admin on Fri Dec 15 15:00:44 GMT 2023
|
PRIMARY | |||
|
200-757-9
Created by
admin on Fri Dec 15 15:00:43 GMT 2023 , Edited by admin on Fri Dec 15 15:00:43 GMT 2023
|
PRIMARY | |||
|
1378001
Created by
admin on Fri Dec 15 15:00:44 GMT 2023 , Edited by admin on Fri Dec 15 15:00:44 GMT 2023
|
PRIMARY | |||
|
CHEMBL717
Created by
admin on Fri Dec 15 15:00:43 GMT 2023 , Edited by admin on Fri Dec 15 15:00:43 GMT 2023
|
PRIMARY | |||
|
DTXSID0025527
Created by
admin on Fri Dec 15 15:00:43 GMT 2023 , Edited by admin on Fri Dec 15 15:00:43 GMT 2023
|
PRIMARY | |||
|
6279
Created by
admin on Fri Dec 15 15:00:44 GMT 2023 , Edited by admin on Fri Dec 15 15:00:44 GMT 2023
|
PRIMARY | |||
|
Medroxyprogesterone Acetate
Created by
admin on Fri Dec 15 15:00:43 GMT 2023 , Edited by admin on Fri Dec 15 15:00:43 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (UV)
EP
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
MEDROXYPROGESTERONE ACETATE Impurity E.
In the chromatogram obtained with solution (1):the area of any peak corresponding to impurity C, E or I is not greater than 2 times the area of the principal peak obtained with solution (3) (0.2%).
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
The following peaks are eluted at the following relative retention with reference to the peak of medroxyprogesterone acetate (retention time about 27 minutes): impurity C about 0.8. The test is not valid unless in the chromatogram obtained with solution (4) the resolution factor between the peaks due to impurity G and due to medroxyprogesterone acetate is at least 3.3. In the chromatogram obtained with solution (1):the area of any peak corresponding to impurity C, E or I is not greater than 2 times the area of the principal peak obtained with solution (3) (0.2%).
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
MEDROXYPROGESTERONE ACETATE Impurity I.
The following peaks are eluted at the following relative retention with reference to the peak of medroxyprogesterone acetate (retention time about 27 minutes): impurity I about 0.5. In the chromatogram obtained with solution (1):the area of any peak corresponding to impurity C, E or I is not greater than 2 times the area of the principal peak obtained with solution (3) (0.2%).
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 1.5
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 2.6
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
MEDROXYPROGESTERONE ACETATE Impurity F.
Amount not specified.
|
||
|
IMPURITY -> PARENT |
MEDROXYPROGESTERONE ACETATE Impurity H.
The following peaks are eluted at the following relative retention with reference to the peak of medroxyprogesterone acetate (retention time about 27 minutes): impurity H about 0.65.
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 1.8
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
MEDROXYPROGESTERONE ACETATE Impurity B. In the chromatogram obtained with solution (1):the area of any peak corresponding to impurity B is not greater than 0.7 times the area of the principal peak obtained with solution (2) (0.7%).
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
MEDROXYPROGESTERONE ACETATE Impurity G.
In the chromatogram obtained with solution (1):the area of any peak corresponding to impurity G, when multiplied by a correction factor of 2.6, is not greater than 2 times of the area of the principal peak obtained with solution (3) (0.2%).
|
||
|
PARENT -> IMPURITY |
For the calculation of contents, multiply the peak areas by 0.2
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
MEDROXYPROGESTERONE ACETATE Impurity D.
In the chromatogram obtained with solution (1):the area of any peak corresponding to impurity D is not greater than the area of the principal peak obtained with solution (2) (1.0%).
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
MEDROXYPROGESTERONE ACETATE Impurity A.
In the chromatogram obtained with solution (1):the area of any peak corresponding to impurity A, when multiplied by a correction factor of 1.5, is not greater than 3 times of the area of the principal peak obtained with solution (3) (0.3%).
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |